Historical Stock Price
AIM historical stock prices picture
AIM ImmunoTech (AIM) has the following price history information. Looking back at AIM historical stock prices for the last five trading days, on August 08, 2022, AIM opened at $0.72, traded as high as $0.75 and as low as $0.70, and closed at $0.75. Trading volume was a total of 103.80K shares. On August 09, 2022, AIM opened at $0.75, traded as high as $0.75 and as low as $0.72, and closed at $0.73. Trading volume was a total of 74.50K shares. On August 10, 2022, AIM opened at $0.74, traded as high as $0.77 and as low as $0.73, and closed at $0.76. Trading volume was a total of 132.30K shares. On August 11, 2022, AIM opened at $0.75, traded as high as $0.78 and as low as $0.73, and closed at $0.76. Trading volume was a total of 142.00K shares. On August 12, 2022, AIM opened at $0.77, traded as high as $0.80 and as low as $0.74, and closed at $0.77. Trading volume was a total of 128.60K shares.

AIM Historical Stock Prices By Date:

AIM historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into AIM ImmunoTech shares, starting with a $10,000 purchase of AIM, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 08/14/2012
End date: 08/12/2022
Start price/share: $0.48
End price/share: $0.77
Dividends collected/share: $0.00
Total return: 60.42%
Average Annual Total Return: 4.84%
Starting investment: $10,000.00
Ending investment: $16,042.43
Years: 10.00
Date Open High Low Close Volume
08/08/2022 $0.72 $0.75 $0.70 $0.75 103.80K
08/09/2022 $0.75 $0.75 $0.72 $0.73 74.50K
08/10/2022 $0.74 $0.77 $0.73 $0.76 132.30K
08/11/2022 $0.75 $0.78 $0.73 $0.76 142.00K
08/12/2022 $0.77 $0.80 $0.74 $0.77 128.60K
AIM ImmunoTech is an immuno-pharma company that is focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders. Co.'s primary pharmaceutical product platform consists of Ampligen® and Alferon N Injection®. Ampligen® is approved for sale in Argentina for severe Chronic Fatigue Syndrome (CFS) and is an experimental drug in the U.S. undergoing clinical development for the treatment of certain cancers and myalgic encephalomyelitis/CFS. Alferon N Injection® is a natural alpha interferon for the intralesionaltreatment of refractory or recurring external genital warts in patients 18 years of age or older.
Date Close
08/08/2022$0.75
08/09/2022$0.73
08/10/2022$0.76
08/11/2022$0.76
08/12/2022$0.77
AIM is categorized under the Healthcare sector; below are some other companies in the same sector:

AIMT Historical Stock Prices
AIPT Historical Stock Prices
AIQ Historical Stock Prices
AIRM Historical Stock Prices
AITB Historical Stock Prices
AKAO Historical Stock Prices
AKBA Historical Stock Prices
AKCA Historical Stock Prices
AKER Historical Stock Prices
AKRO Historical Stock Prices

Email EnvelopeFree AIM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts


AIM Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.